Bio-Techne director awarded 1,381 indirect RSUs
BIO-TECHNE Corp (TECH) director Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on 2026-08-17, held through a significant other.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) director Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on 2026-08-17, held through a significant other. Each unit represents a contingent right to receive one share of BIO-TECHNE common stock, vesting in three annual installments in 2027, 2028, and 2029.
The filing also lists existing option and RSU awards with various exercise prices from $53.60 to $120.46 and expiration dates through 2035, along with direct holdings of 2,680 common shares and 576 indirect common shares. No sales or option exercises are reported.
Insider Trade Summary
Grant/Award: 1,381 shares
Grant/Award
15 txns
Insider
Herr Amy E.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F7, F11 | 1,381 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F6 | -- | -- | -- |
| holding | Restricted Stock Units F7, F8 | -- | -- | -- |
| holding | Restricted Stock Units F7, F9 | -- | -- | -- |
| holding | Restricted Stock Units F7, F10 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 2,239 contracts for 858 underlying shares (Indirect, By significant other);
Stock Option (Right to Buy) — 14,283 contracts (Indirect, By significant other);
Stock Option (Right to Buy) — 6,192 contracts (Direct);
Common Stock — 2,680 shares (Direct);
Common Stock — 576 shares (Indirect, By significant other)
Footnotes (11)
- F1. Fully vested.
- F2. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- F3. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F4. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- F5. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
- F6. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- F7. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F8. 160 restricted stock units vest on 8/15/2027.
- F9. 38 restricted stock units vest on 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
- F10. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
- F11. 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029.
Key Figures
RSU grant: 1,381 units
Direct common shares held: 2,680 shares
Indirect common shares held: 576 shares
+5 more
8 metrics
RSU grant
1,381 units
Indirect Restricted Stock Units granted on 2026-08-17, each for one share of common stock
Direct common shares held
2,680 shares
Direct ownership of BIO-TECHNE common stock after reported transactions
Indirect common shares held
576 shares
Indirect ownership through significant other after reported transactions
Option exercise price range
$53.6000–$120.4600
Exercise prices of reported stock options on BIO-TECHNE common stock
Earliest option expiration
2027-08-05
Expiration date for a stock option with $66.9700 exercise price, indirect ownership
Latest option expiration
2035-10-30
Expiration date for a stock option with $60.9600 exercise price, direct ownership
RSUs vesting 8/17/2027
460 units
Portion of the 1,381 RSU grant vesting on 8/17/2027
RSUs vesting 8/17/2029
461 units
Final tranche of the 1,381 RSU grant vesting on 8/17/2029
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), indirect, exercise price, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with specified exercise prices and expiration dates"
indirect financial
"Ownership type reported as indirect, by significant other"
exercise price financial
"Stock options show exercise price values such as 66.9700 and 53.6000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"Options to purchase shares vest on specific future dates"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BIO-TECHNE (TECH) director Amy E. Herr acquire in this Form 4?
Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on BIO-TECHNE common stock. The RSUs are held through a significant other and convert one-for-one into shares as they vest over three years starting in 2027.
How do the new RSUs for BIO-TECHNE (TECH) vest for Amy E. Herr?
The 1,381 Restricted Stock Units vest in three tranches: 460 units on 8/17/2027, 460 units on 8/17/2028, and 461 units on 8/17/2029. Each vested unit entitles the holder to receive one share of BIO-TECHNE common stock.
What common stock holdings does Amy E. Herr report for BIO-TECHNE (TECH)?
The filing lists 2,680 shares of common stock held directly and 576 shares held indirectly through a significant other. These figures represent reported ownership positions as of the 2026-08-17 transaction date in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
